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Polymorphisms in chemokine receptors play an important role in the progression of cervical intraepithelial neopla-
sia (CIN) to cervical cancer (CC). Our study examined the association of CCR2-64I (rs1799864) and CCR5-Δ32 (rs333) 
polymorphisms with susceptibility to develop cervical lesion (CIN and CC) in a Brazilian population. The genotyping 
of 139 women with cervical lesions and 151 women without cervical lesions for the CCR2-64I and CCR5-Δ32 polymor-
phisms were performed using polymerase chain reaction-restriction fragment length polymorphism. The individuals 
carrying heterozygous or homozygous genotypes (GA+AA) for CCR2-64I polymorphisms seem to be at lower risk for 
cervical lesion [odds ratio (OR) = 0.37, p = 0.0008)]. The same was observed for the A allele (OR = 0.39, p = 0.0002), 
while no association was detected (p > 0.05) with CCR5-Δ32 polymorphism. Regarding the human papillomavirus 
(HPV) type, patients carrying the CCR2-64I polymorphism were protected against infection by HPV type 16 (OR = 
0.35, p = 0.0184). In summary, our study showed a protective effect of CCR2-64I rs1799864 polymorphism against the 
development of cervical lesions (CIN and CC) and in the susceptibility of HPV 16 infection.
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Infections by oncogenic types of human papillomavi-
rus (HPV) are found in 99% of women with cervical cancer 
(CC) (de Oliveira et al. 2013). Therefore, this virus is classi-
fied as the most important carcinogenic risk factor accord-
ing to the criteria of the International Agency for Research 
on Cancer (Bonanni et al. 2015). Among more than 120 
types of HPV have been identified, 18 of these are classi-
fied as high-risk oncogenic (Bouvard et al. 2009, Bernard 
et al. 2010). However, the majority of women infected with 
HPV will not develop cervical carcinoma, since the carci-
nogenic process depends on several other genetic, environ-
mental, and immune factors (Zheng et al. 2006).
The loss of cell cycle control mechanism, infiltra-
tion of leukocyte, and of other immunocompetent cells, 
as well as the altered expression of immune response 
genes, have been considered critical in neoplasms cervi-
cal pathogenesis and progression for CC (Evans et al. 
1997, Ghaderi et al. 2000, O’Brien et al. 2001).
Among the gene products present into cervical mu-
cosa, chemokines and their receptor have shown a key 
role in immunity against cervical tumours (Ghaderi et 
al. 2000, Ohta et al. 2002). Chemokines are chemoat-
tractant proteins of low molecular weight that promote 
adhesiveness of target cells; then the angiogenesis pro-
cess drive homing of phagocytes and lymphocytes into 
secondary lymphoid organs (Rossi & Zlotnik 2000, Kle-
ine-Lowinski et al. 2003, Zheng et al. 2006). The recep-
tors for chemokines are mainly expressed on immune 
cells and assist in the differentiation and migration of 
these cells to inflamed tissues (Bromley et al. 2005).
Chemokine receptor (CCR)5 is the major receptor for 
the chemokine and their ligands are the macrophage in-
flammatory protein (MIP)-1α/chemokine ligand (CCL)3, 
MIP-1β/CCL4, and regulated on activation, normal T cell 
expressed and secreted/CCL5 (Lehner 2002, Al-Abdul-
hadi & Al-Rabia 2010, Ahmadabadi et al. 2012). Polymor-
phic variations in this gene, in particular the Δ32 mutation 
(a 32 bp deletion in the CCR5 gene) leads to decreased ex-
pression and dysfunction of CCR5 receptor (Nahon et al. 
2008, Ahmadabadi et al. 2012). Studies report that indi-
viduals homozygotes for CCR5-Δ32 (rs333) gene have re-
duced risk for asthma and early-onset myocardial infarc-
tion, attenuation of severity in rheumatoid arthritis, and 
slower acquired immune deficiency syndrome (AIDS) 
progression (Berger et al. 1999, Hall et al. 1999, Zapico 
et al. 2000, González et al. 2001). In addition CCR5, to-
gether with CCR2, act as co-receptors for human immu-
nodeficiency virus-1 (Zheng et al. 2006).
CCR 2 is the receptor for CCL 2, also known as 
monocyte chemoattractant protein (MCP)-1, being as-
sociated with carcinogenesis and angiogenesis (Charo et 
al. 1994, Zhang et al. 2003, Koide et al. 2004, Huang 
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et al. 2013). The single nucleotide polymorphism at co-
don 64 (CCR2-64I, rs1799864) of CCR2 gene that encodes 
isoleucine (ATC) instead of valine (GTC) has been widely 
studied, and there are reports of association between this 
polymorphism and the protective effect in the progression 
of inflammatory diseases such as multiple sclerosis (Mi-
yagishi et al. 2003), carotid atherosclerosis (Nyquist et al. 
2009), and in development of breast cancer (Zafiropoulos 
et al. 2004). However, conflicting results on the role of the 
CCR5 and CCR2 polymorphisms in the development of the 
CC have been reported so far (Coelho et al. 2005, Zheng et 
al. 2006, Ivansson et al. 2007, Chatterjee et al. 2010).
Therefore, the aim of this study was to analyse the as-
sociation for CCR2-64I and CCR5-Δ32 polymorphisms 
with development of cervical intraepithelial neoplasia 
(CIN) or CC in women infected by HPV from Northeast 
Region of Brazil.
SUBJECTS, MATERIALS AND METHODS
Population - The present study was a hospital-based 
cross-sectional prospective one carried out in the outpa-
tient clinics of the Lower Genital Tract Pathology Clinic 
at the Women’s Healthcare Center of the Prof Fernando 
Figueira Institute of Integrated Medicine, Recife, state of 
Pernambuco, Brazil. Patients were selected by spontane-
ous demand from January 2009 until 2011 and the study 
population consisted of 290 sexually active women rang-
ing between 16-75 years old. Information was collected 
from all women pertaining to their age, smoking, alco-
hol consumption, number of offspring, number of sexual 
partners, and age at first coitus. The inclusion criteria 
was as follows: women with oncotic cytology submitted 
to Papanicolaou test (cytological) according to Bethesda 
System terminology (Solomon et al. 2002) performed on 
the state accredited networks, presenting diagnostic of 
CIN of low-grade and high-grade or CC, and confirmed 
by histological analysis. Subjects were evaluated for 
clinical features of other sexually transmitted infections 
on history and examination. Patients that were previous-
ly submitted to radiotherapy or chemotherapy to inva-
sive CC were excluded. The Institutional Ethical Com-
mittee approved this study (protocol 355/08). Informed 
written consent was taken from the women informing 
them about the background of the study, risks and ben-
efits, and voluntary nature of participation. After histo-
logical analysis, patients were stratified according to the 
presence or absence of cervical lesion (CIN or CC) as 
case and control groups, respectively.
Clinical samples - Cervical smears were obtained us-
ing Cytobrushes. Each Cytobrush was packed in a Tris-
ethylenediamine tetraacetic acid (EDTA) buffer solution 
(Tris-HCl 10 mM and EDTA 1 mM pH 8.0) and con-
served at -20ºC until analysis.
DNA extraction - Genomic DNA extraction was per-
formed from 300 µL of vaginal fluid from each study 
subject, following the manufacturer’s instructions of 
the kit Wizard® Genomic DNA Purification (Promega, 
USA). The analyses samples were executed the Labora-
tory of Genetics, Biochemistry, and DNA Sequencing at 
Rural Federal University of Pernambuco.
HPV detection and typing - Amplification of human 
β-globin gene segment was used as an internal control 
for DNA quality and samples negative for this assay 
were excluded from analysis. Then, our samples were 
tested for HPV presence using MY09/11, GP05+ and 
GP06+ consensus primers by polymerase chain reaction 
(PCR) (Tavares et al. 2014). The typing of high-risk HPV 
(HR-HPV) 16, 18, 31, and 33 was performed using spe-
cific primers (da Silva et al. 2009, Tavares et al. 2015).
Analysis of the CCR2-64I polymorphism - The 
CCR2-64I polymorphism was analysed through PCR 
followed by restriction fragment length polymorphism 
(Coelho et al. 2005). DNA was amplified using primers 
sense 5’-TTGTGGGCAACATGATGG-3’ and antisense 
5’-GCATTCCCAAAGACCCACTC-3’. The PCR prod-
ucts of 163 bp length were then digested with BsaBI re-
striction enzyme. The fragments originated after of the 
use the restriction enzyme, 163 bp for G allele, and 145 
and 18 bp for A allele were revealed using 3% agarose 
gel stained with gel red (UNISCIENCE).
Analysis of the CCR5-Δ32 polymorphism - The 
CCR5-Δ32 polymorphism was analysed through 
PCR (Kristiansen et al. 2001) using primers sense 
5’-CTTCATCATCCTC-CTGACAATCG-3’ and anti-
sense 5’-GACCAGCCCCAAGTTGACTATC-3’. PCR 
products of 262 bp for CCR5 wild-type allele and 230 bp 
for CCR5-Δ32 allele were detected with 3% agarose gel 
stained with gel red (UNISCIENCE).
Sequencing - A total of 20% of the all samples (ran-
domly chosen) was submitted to bidirectional sequenc-
ing (MegaBACE 1000 DNA sequencer; GE Healthcare, 
USA) in order to double-check the genotyping results for 
each polymorphism (Tavares et al. 2015).
Statistical analyses - Univariate statistical analysis 
was performed using the BioEstat 5.0 software. The study 
was cross-sectional with independent samples consisting 
of nominal data (genotypes). The influence of each poly-
morphism on the risk for development of (pre) neoplastic 
cervical disease was estimated by odds ratio (OR) and a 
95% confidence interval (CI). Allele frequencies were es-
timated by direct counting. Comparison between geno-
typic frequencies of patients and control groups was per-
formed by chi-square test and Fisher’s exact test was used 
to compare the allele frequencies in contingency tables.
For identification of relevant risk factors, a logistic 
regression analysis was carried out (comparing HPV-
positive women with history of lesions with HPV-positive 
women with no history of lesions or CC). This modelled 
the influence of genetic polymorphisms, HPV 16 single 
infection or multiple HPV strains co-infection, smoking 
and alcohol consumption on the risk of developing high-
grade squamous intraepithelial lesions. The OR and their 
respective 95% CI were determined. The R software 
v.3.0.2 (R-project.org/) was used to perform the regres-
sion analysis. Power analysis was performed through 
G*Power software v.3.1.9.2 (Faul et al. 2007). All p-values 
≤ 0.05 were considered statistically significant.
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RESULTS
Within the 290 HPV positive enrolled women, 139 
had cervical lesions (CIN or CC) (HPV+L) while the 151 
had no cervical lesions (HPV+). When considering the 
prevalence of type-specific HR-HPV infection, we ob-
served that 38.8% of the patients had HPV 16, 22.3% HPV 
18, 2.9% HPV 31, 3.6% HPV 33, and 14.4% other HPV 
types. Furthermore, the presence of co-infection by HPV 
types 16/18 was found in 18% of the patients (Table I). 
Moreover, when the patients were stratified according to 
TABLE I
Human papillomavirus (HPV) genotypes prevalence and histologic diagnosis
Types
CIN I
(n = 40) 
n (%)
CIN II/III
(n = 87)
n (%)
CC
(n = 12) 
n (%)
Total
(n = 139)
n (%)
HPV 16 10 (25) 38 (43.7) 6 (50) 54 (38.8)
HPV 18 9 (22.5) 20 (22.9) 2 (16.7) 31 (22.3)
HPV 31 2 (5) 2 (2.3) 0 (0) 4 (2.9)
HPV 33 0 (0) 4 (4.6) 1 (8.3) 5 (3.6)
Others HPV 14 (35) 5 (5.8) 1(8.3) 20 (14.4)
Co-infection (16/18) 5 (12.5) 18 (20.7) 2 (16.7) 25 (18)
CC: cervical cancer; CIN: cervical intraepithelial neoplasia.
TABLE II
Genotypic distribution of the CCR2-64I and CCR5-Δ32 gene polymorphisms in human papillomavirus (HPV) positive patients 
with cervical intraepithelial neoplasia (CIN) and cervical cancer (CC) (HPV+L) or without cervical lesions (HPV+)
SNP
HPV+
(n = 151)
n (%)
HPV+L
(n = 139)
n (%)
χ2
(p)
OR 
(95% CI) pa
CCR2 64I genotypes
GG 99 (65.6) 116 (83.4) 1
GA 43 (28.4) 21 (15.1) 8.820
(0.0047)
0.42
(0.23-0.75)
0.0047
AA 9 (6) 2 (1.5) 5.367
(0.0447)
0.19
(0.04-0.89)
0.0447
AA + GA x GG 52/99 (52.5) 23/116 (19.8) 12.082 
(0.0005)
0.37
(0.21-0.66)
0.0008
Allele
G 241 (79.8) 253 (91) 14.393 
(0.0001)
1
A 61 (20.2) 25 (9) 0.39
(0.23-0.64)
0.0002
CCR5-Δ32 genotypes
WT/WT 141 (93.3) 125 (89.9) 1
WT/Δ32 10 (6.7) 14 (10.1) 1.134
(0.2868)
1.57
(0.67-3.68)
0.3943
Δ32/Δ32 0 (0) 0 (0) ND ND ND
WT/Δ32 + Δ32/Δ32 x WT/WT 10/141 (7) 14/125 (11.2) 1.134
(0.2868)
1.57
(0.67-3.68)
0.3943
Allele
WT 292 (96.7) 264 (94.9) 1
Δ32 10 (3.3) 14 (5.1) 1.085 
(0.2975)
1.54
(0.67-3.54)
0.4047
a: value of the odds ratio (OR); CI: confidence interval; ND: not determined; SNP: single nucleotide polymorphism; WT: wild-
type; χ2: chi-square test. Bolded values mean significant values.
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the severity of cervical lesions, 28.78% (40/139) exhibited 
CIN I (low-degree of lesion), 62.58% (87/139) had CIN II 
or III (high-degree of lesion), and 8.63% (12/139) had CC.
Among the 139 HPV+L, five risk factors for cervical 
lesions were analysed: smoking, alcohol consumption, 
number of offspring, number of sexual partners, and age 
at first coitus. With the 139 HPV+L, 32.37% (45/139) 
reported smoking, 60.03% (89/139) alcohol consump-
tion, 28.78% (40/139) number of offspring > 3, 20.17% 
(24/119) had number of sexual partners > 4, and 59.71% 
(83/139) had first coitus with ≤ 16 years old.
The distribution of CCR2-64I and CCR5-Δ32 poly-
morphisms genotypes in 139 women with cervical le-
sions (CIN or CC) and 151 HPV+ were according to the 
Hardy-Weinberg equilibrium. A significant difference 
in the distribution of CCR2-64I polymorphism between 
HPV+ L and HPV+ was observed using a dominant ge-
netic model (OR = 0.37; p = 0.0005), being the variant 
carrier (GA+AA) associated with protection to cervi-
cal lesions (Table II). When considering the CCR5-Δ32 
polymorphism, no statistical difference between HPV+-
L and HPV+ was observed (p = 0.3943) (Table II).
Statistical significant association was found be-
tween CCR2-64I polymorphism and susceptibility to 
HPV 16 infection (OR = 0.35; p = 0.0184) (Table III); 
the CCR5-Δ32 variant did not show any association with 
HPV types studied.
Patients clinical features are shown in Table IV. There 
were no significant statistical differences between CCR2-
64I and CCR5-Δ32 polymorphisms with age, smoking, 
alcohol consumption, number of offspring, number of 
sexual partners, or age at first coitus (p > 0.05).
DISCUSSION
In this study, we examined the possible association 
between CCR2-64I and CCR5-Δ32 polymorphisms and 
the presence of cervical lesions (CIN or CC) in HPV in-
fected women from Northeast Region of Brazil.
The CCRs genes CCR5 and CCR2 have been associ-
ated with carcinogenesis and angiogenesis (Zheng et al. 
2006), inflammatory disorders, and autoimmune diseas-
es (Rossi & Zlotnik 2000). Immunological studies, re-
garding to immune response genes, showed a significant 
decrease in intraepithelial macrophages (Tay et al. 1987), 
Langerhans cells (Spinillo et al. 1993), and cytotoxic T 
lymphocytes in CIN advanced (Evans et al. 1997).
The CCR2-64I polymorphism has been reported to 
influence several diseases as multiple sclerosis (Miyag-
TABLE III
Genotypic distribution of the CCR2-64I and CCR5-Δ32 polymorphisms in human papillomavirus  
(HPV)-16 positive patients and in patients with HPV genotypes other than type 16
SNP
Other HPV
(n = 85)
n (%)
HPV 16
(n = 54) 
n (%)
χ2
(p)
OR 
(95% CI) pa
CCR2 64I genotypes
GG 69 (81.1) 47 (87.1) 1
GA 1 (1.1) 6 (11.1) 13.76
(0.001)
8.80
(1.02-75.56)
0.0509
AA 15 (17.8) 1 (1.8) 0.09
(0.01-0.77)
0.0167
GG/GA + AA 69/16 47/7 0.64
(0.24-1.68)
0.5015
Allele
G 139 (81.7) 100 (92.6) 6.93
(0.031)
1
A 31 (18.3) 8 (7.4) 0.35  
(0.15-0.81)
0.0184
CCR5-Δ32 genotypes
WT/WT 80 (94.1) 46 (85.2) 1
WT/Δ32 5 (5.9) 8 (14.8) 3.01
(0.221)
2.78
(0.86-9.01)
0.1432
Δ32/Δ32 0 0 ND
WT/WT x WT/Δ32 + Δ32/32 80/5 46/8
Alelle
WT 165/170 (97.1) 100/108 (92.6) 1
Δ32 5/170 (2.9) 8/108 (7.4) 2.86
(0.239)
2.64
(0.84-8.29)
0.1534
a: value of the odds ratio (OR); CI: confidence interval; ND: not determined; SNP: single nucleotide polymorphism; WT: wild-
type; χ2: chi-square test. Bolded values mean significant values.
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ishi et al. 2003), carotid atherosclerosis (Nyquist et al. 
2009), breast cancer (Zafiropoulos et al. 2004), AIDS 
progression (Smith et al. 1997, Mulherin et al. 2003), 
and CIN or CC (Coelho et al. 2005, Ivansson et al. 2007, 
Chatterjee et al. 2010). Our results showed a protective 
effect of CCR2-64I polymorphic variant against the de-
velopment of cervical lesions (OR = 0.37); Coelho et al. 
(2005) found the same outcome in a Portuguese popula-
tion. Nevertheless, Chatterjee et al. (2010) and Ivansson 
et al. (2007) reported that the A allele conferred risk to 
development of CC in African and Swedish women. The 
contradictory results on the A allele in relation to the de-
velopment of CIN or CC (Coelho et al. 2005, Zheng et al. 
2006, Ivansson et al. 2007) might be due to its conflicting 
role in the macrophages recruitment reported by some 
authors. Wallin et al. (1999) suggested that mutant al-
lele CCR2-64I can be linked with decreased macrophag-
es recruitment in the process of tumour angiogenesis, 
which could be a key during progression of cervical ne-
TABLE IV
Genotypic distribution of the CCR2-64I and CCR5-Δ32 polymorphisms in patients with cervical lesions  
(cervical intraepithelial neoplasia and cervical cancer and clinical features
Clinical features
CCR2-64I
A/P (n = 139) G/G G/A + A/A
χ2
(p)
OR 
(95% CI) pa
Smoking P 45 36 9 0.4484 1.42
(0.56-3.60)
0.6072
A 94 80 10
Alcohol consumption P 89 77 12 0.1947 0.55
(0.41-4.36)
0.2896
A 50 39 11
Number of offspring > 3 40 33 7 0.7452 1.18
(0.42-3.28)
0.9521
≤ 3 79 67 12
Number of sexual partners > 4 24 21 3 0.6038a 0.70
(0.18-2.65)a
0.8360a
≤ 4 95 79 16
Age at first coitus ≤ 16 83 67 16 0.2916 1.67
(0.63-4.37)
0.4111
≤ 16 56 49 7
CCR5-Δ32 
Clinical features A/P (n = 139) Wt/Wt Wt/Δ32 + Δ32/Δ32
χ2
(p)
OR 
(95% CI) pa
Smoking P 45 40 5 0.6222 1.34
(0.41-4.36)
0.8561
A 94 86 8
Alcohol consumption P 89 79 10 0.0529 6.20
(0.77-49.96)
0.1077
A 50 49 1
Number of offspring > 3 40 36 4 0.9827 0.76
(0.27-3.49)
0.7637
≤ 3 79 71 8
Number of sexual partners > 4 24 22 2 0.7499a 0.77
(0.15 -3.78)a
0.9517
≤ 4 95 85 10
Age at first coitus ≤ 16 83 76 7 0.6506 0.76
(0.24-2.41)
0.8761
> 16 56 50 6
a: were used a total of 119 patients; A: absence of the characteristic; CI: confidence interval; OR: odds ratio of A x G alleles; P: 
presence of the characteristic; WT: wild-type; χ2: chi-square test.
oplasia to CC. However, Chatterje et al. (2010) proposed 
that the raised attraction of the macrophages through the 
increased expression of MCP-1 could be auxiliary in the 
process of destruction or progression of tumour. These 
discordant findings reinforce the possibility of several 
factors associated with the multifactorial neoplastic de-
velopment, including the difference in ethnic origin of 
the populations studied, sample sizes, and the low per-
centage of the mutant allele (CCR2-64I).
Studies reported that CCR5-Δ32 is involved in slow-
er AIDS progression (Berger et al. 1999), in decreasing 
the severity of rheumatoid arthritis (Zapico et al. 2000), 
and in the reduced risk to asthma (Hall et al. 1999). To 
our knowledge until now, only one study conducted by 
Zheng et al. (2006) in a Swedish population related the 
CCR5-Δ32 polymorphism with CC. The authors ob-
served that individual carriers of the allele Δ32 had 4.58 
fold-increased risk to HPV infection, but they did not 
found association in relation to progression of cervical 
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lesion. In our study, we did not observe any association 
of Δ32 variant with development of cervical lesion (p > 
0.05). However, to clarify the role of this genotype in 
both HPV infection and progression for cervical lesion, 
the CCR5-Δ32 polymorphism should be tested in other 
populations from different ethnic background.
Regarding to prevalence of HPV infection, we found 
that the more frequent types were HPV 16 and 18 (38.8% 
and 22.3%, respectively). The prevalence of HPV 31 was 
2.8% and HPV 33 was 3.5%. Tavares et al. (2014) found 
similar results in a study conducted at Recife with 142 
HPV positive women with cervical lesion. Silva et al. 
(2003) and Rabelo-Santos et al. (2003) observed that 
HPV type 16 was the most prevalent virus in all Bra-
zilian regions, but there were variation regarding the 
frequencies of the type 16 in relation to other types. Fur-
thermore, ours results are in agreement with distribution 
of these HPV types worldwide in women with CC (Li et 
al. 2011). da Silva et al. (2009) evaluated the incidence of 
HPV types in 213 samples cervical of women in Recife, 
finding a higher frequency of HPV 16 (78%), HPV 31 
(15.5%), and lower frequency of HPV 18 (2.8%) when 
compared to our findings. Lorenzato et al. (2000) also 
found higher prevalence of HPV 31 (21.4%) and a lower 
prevalence of HPV 18 (2.4%).
Previous reports have shown that concomitant or se-
quential detection of more than one HPV type it is asso-
ciated with different stages of cervical lesions (Silva et 
al. 2003, da Silva et al. 2009, Tavares et al. 2014). Our 
results are in agreement with the above mentioned find-
ings: in 25 samples co-infected by HPV 16/18, 80% (20) 
had high-grade of cervical lesions (neoplasia intraepi-
thelial cervical II/III or CC).
A protector effect of the CCR2-64I polymorphism 
with the susceptibility of infection by HPV type 16 (OR 
= 0.35) was observed, suggesting a possible relation of 
this genetic variant with protection to HPV-16 infection.
We also compared clinical features from patients 
with genotypic distribution of both CCR2-64I and 
CCR5-Δ32 polymorphisms. However, no significant dif-
ference was observed (p > 0.005). The frequencies of 
CCR2 and CCR5 variants alleles were in agreement with 
a previous study in different diseases and ethnic groups 
(Lawhorna et al. 2013).
Thus, our data suggest that the CCR2-64I polymor-
phism is associated with the protective effect to devel-
opment of cervical lesions as well as in the protection to 
HPV 16 infection.
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